1. Tordo, N, et al. Lyssaviruses. In: Fauquet, CM eds. Virus taxonomy: the classification and nomenclature of viruses. The 8th Report of the International Committee on Taxonomy of Viruses. San Diego: Oxford Academic, 2006, pp. 623–629.
2. WHO. World Health Organization Expert Consultation on Rabies, 5–8 October 2004, First report. World Health Organization Technical report series 931. Geneva: World Health Organization, 2005, pp. 15–19. 105.
3. Arai, YY, et al. New lyssavirus genotype from lesser mouse-eared bats (Myotis blythi), Kyrghyzstan. Emerging Infectious Disease 2003; 9: 333–337.
4. Botvinkin, AD, et al. Novel lyssaviruses isolated from bats in Russia. Emerging Infectious Disease 2003; 9: 1623–1625.
5. Kuzmin, IV, et al. Bat lyssaviruses (Aravan and Khujand) from Central Asia: phylogenetic relationships according to N, P and G gene sequences. Virus Research 2003; 97: 65–79.
6. Kuzmin, IV, et al. Phylogenetic relationships of Irkut and West Caucasian bat viruses within the Lyssavirus genus and suggested quantitative criteria based on the N gene sequence for lyssavirus genotype definition. Virus Research 2005; 111: 28–43.
7. Badrane, H, et al. Evidence for two lyssavirus phylogroups with distinct pathogenicity and immunogenicity. Journal of Virology 2001; 75: 3268–3276.
8. Hanlon, CA, et al. Efficacy of rabies biologics against new lyssaviruses from Eurasia. Virus Research 2005; 111: 44–54.
9. Nel, LH. Vaccines for lyssaviruses other than rabies. Expert Reviews of Vaccines 2005; 4: 553–540.
10. Paweska, JT, et al. Fatal human infection with rabies-related Duvenhage virus, South Africa. Emerging Infectious Disease 2006; 12: 1965–1967.
11. Nel, LH, et al. A comparison of DNA vaccines for the rabies-related virus, Mokola. Vaccine 2003; 21: 2598–2606.
12. Weyer, J. Immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes [Thesis]. Pretoria, South Africa: University of Pretoria, 2006, pp. 127–156.
13. Beuken, E, Vink, C, Bruggeman, CA. One step procedure for screening recombinant plasmids by size. BioTechniques 1998; 24: 748–750.
14. Earl, PL, et al. Preparation of cell cultures and vaccinia virus stocks. In: Current Protocols in Molecular Biology. Indianapolis, IN: John Wiley and Sons, 1998, pp. 16.16.1–16.20.2.
15. Byrd, CM, Hruby, DE. Construction of recombinant vaccinia virus. Cloning into the thymidine kinase locus. In: Isaacs, SN ed. Vaccinia virus and poxvirology. Methods and Protocols. Totowa, NJ: Humana Press, 2005, pp. 31–39.
16. Pasamontes, L, et al. Direct identification of recombinant virus plaques by PCR. Journal of Virological Methods 1991; 35: 137–141.
17. Esposito, J, Condit, R, Objeski, J. The preparation of orthopoxvirus DNA. Journal of Virological Methods 1981; 2: 175–179.
18. Dean, DJ, Abelseth, MK, Atanasiu, P. The fluorescent antibody test. In: Meslin, F-X, Kaplan, MM, Koprowski, H eds. Laboratory Techniques in Rabies, 4th edn.Geneva: World Health Organization, 1996, pp. 88–95.
19. Smith, JS, Yager, PA, Baer, GM. A rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus–neutralizing antibody. In: Meslin, F-X, Kaplan, MM, Koprowski, H eds. Laboratory Techniques in Rabies, 4th edn.Geneva: World Health Organization, 1996, pp. 181–192.
20. Markotter, W, et al. Lagos Bat virus, South Africa. Emerging Infectious Diseases 2006; 12: 504–506.
21. Nel, L, et al. New cases of Mokola virus infection in South Africa: a genotypic comparison of Southern African virus isolates. Virus Genes 2000; 20: 103–106.
22. Familusi, JB, Moore, DL. Isolation of a rabies-related virus from the cerebrospinal fluid of a child with aseptic meningitis. African Journal of Medical Science 1972; 3: 93–96.
23. Familusi, JB, et al. A fatal human infection with Mokola virus. American Journal of Tropical Medicine and Hygiene 1972; 21: 959–963.
24. Boulger, IR, Porterfield, JS. Isolation of a virus from Nigerian fruit bats. Transcripts of the Royal Society of Tropical Medicine and Hygiene 1958; 52: 421–424.
25. Sureau, P, Tignor, GH, Smith, AL. Antigenic characterization of the Bangui strain (ANCB-672d) of Lagos bat. Annals of Virology 1980; 131: 25–32.
26. Mebatsion, T, Cox, JH, Frost, JW. Isolation and characterization of 115 street rabies virus isolates from Ethiopia by using monoclonal antibodies: identification of 2 isolates as Mokola and Lagos bat viruses. Journal of Infectious Diseases 1992; 166: 972–977.
27. Fooks, AR. The challenge of emerging lyssaviruses. Expert Review of Vaccines 2004; 3: 89–92.
28. Badrane, H, Tordo, N. Host switching in Lyssavirus history from the Chiroptera to the Carnivora orders. Journal of Virology 2001; 75: 8096–8104.
29. Markotter, W, et al. Isolation of Lagos bat virus from water mongoose. Emerging Infectious Diseases 2006; 12: 1913–1918.
30. Kieny, M-P, et al. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 1984; 312: 163–166.
31. Rupprecht, CE, Kieny, M-P. Development of a vaccinia-rabies glycoprotein recombinant virus vaccine. In: Campbell, JB, Charlton, KM eds. Rabies. Boston, USA: Kluwer Academic Publishers, 1988, pp. 335–364.
32. Tordo, N, et al. Structure and expression in baculovirus of the mokola virus glycoprotein: an efficient recombinant vaccine. Virology 1993; 194: 59–69.
33. Bahloul, C, et al. DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses. Vaccine 1998; 16: 417–425.
34. Jallet, C, et al. Chimeric lyssavirus glycoprotein genes with increased immunological potential. Journal of Virology 1999; 73: 225–233.
35. Bourhy, H, Kiss, B, Tordo, N. Molecular diversity of the lyssavirus genus. Virology 1993; 194: 70–81.
36. Goto, H, et al. Expression of the nucleoprotein of rabies virus in Escherichia coli and mapping of antigenic sites. Archives of Virology 1995; 140: 1061–1074.
37. Dietzschold, B, et al. Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein. Proceedings of the National Academy of Sciences USA 1987; 84: 9165–9169.
38. Lodmell, DL, Smith, JS, Esposito, JJ. Cross-protection of mice against a global spectrum of rabies virus variants. Journal of Virology 1995; 69: 4957–5962.
39. Drings, A, et al. Is there and advantage to including the nucleoprotein in a rabies glycoprotein subunit vaccine? Vaccine 1999; 17: 1549–1557.
40. Perry, LL, Lodmell, DL. Role of CD4+ and CD8+ T cells in murine resistance to street rabies virus. Journal of Virology 1991; 65: 3429–3434.
41. Hooper, DC, et al. Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. Journal of Virology 1998; 72: 3711–3719.
42. Faber, M, et al. Over-expression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune responses. Journal of Virology 2002; 76: 3374–3381.